FuzzyBot: Importing a new version from external source

2024-03-19T08:49:44Z

Importing a new version from external source

New page

===Glargine insulin===
{{main|Insulin glargine}}
Sanofi-[[Aventis]] developed glargine as a longer-lasting insulin analogue, and sells it under the brand name Lantus. It was created by modifying three amino acids. Two positively charged [[arginine]] molecules were added to the C-terminus of the B-chain, and they shift the isoelectric point from 5.4 to 6.7, making glargine more soluble at a slightly acidic [[pH]] and less soluble at a physiological pH. Replacing the acid-sensitive [[asparagine]] at position 21 in the A-chain by [[glycine]] is needed to avoid deamination and dimerization of the arginine residue. These three structural changes and formulation with zinc result in a prolonged action when compared with biosynthetic human insulin. When the pH 4.0 solution is injected, most of the material precipitates and is not bioavailable. A small amount is immediately available for use, and the remainder is sequestered in subcutaneous tissue. As the glargine is used, small amounts of the precipitated material will move into solution in the bloodstream, and the basal level of insulin will be maintained up to 24 hours. The onset of action of subcutaneous insulin glargine is somewhat slower than NPH human insulin. It is clear solution as there is no zinc in formula. The biosimilar insulin glargine-yfgn (Semglee) was approved for medical use in the United States in July 2021, and in the European Union in March 2018.

Translations:Insulin analog/9/en - Revision history

FuzzyBot: Importing a new version from external source